Novo Nordisk's Wegovy study shows 10% weight loss sustainment in 15 months, with 17% side effect withdrawals.
Novo Nordisk's study reveals that Wegovy, a weight loss drug for obesity or overweight individuals with comorbidities like high blood pressure, helped participants lose 10% of their body weight in the first 15 months and sustain this weight loss over four years with continued use. Out of the 17,000 participants involved in the study, around 17% experienced side effects, mainly nausea, and withdrew from the study. More research is required to understand long-term maintenance strategies for weight loss medication users.
May 20, 2024
34 Articles